Table 3.

Summary of adverse events (safety set)

	SHR0302 4 mg [n = 35]		SHR0302 8 mg [n = 35]		Placebo [n = 35]
	No. of cases (%)	No. of events	No. of cases (%)	No. of events	No. of cases (%)	No. of events
All AEs	21 (60.0)	43	24 (68.6)	62	18 (51.4)	33
AEs during screening	0	0	0	0	0	0
TEAEs	21 (60.0)	43	24 (68.6)	62	18 (51.4)	33
Moderate/severe TEAE	3 (8.6)	4	0	0	1 (2.9)	4
Serious TEAE	2 (5.7)	2	1 (2.9)	1	0	0
TEAE leading to death	0	0	0	0	0	0
TEAE affecting the administration of the study drug	3 (8.6)	3	2 (5.7)	2	1 (2.9)	1
TEAE resulting in study withdrawal	3 (8.6)	3	1 (2.9)	1	1 (2.9)	1
Preferred term, frequency ≥5% in any group
Tri-iodothyronine free increased	2 (5.7)		1 (2.9)		4 (11.4)
Transaminases increased	2 (5.7)		1 (2.9)		3 (8.6)
Blood creatine phosphokinase increased	1 (2.9)		2 (5.7)		0
Blood pressure increased	0		2 (5.7)		0
Weight decreased	0		0		2 (5.7)
Upper respiratory tract infection	2 (5.7)		1 (2.9)		0
Folliculitis	0		2 (5.7)		0
Urinary tract infection	0		2 (5.7)		0
Hyperlipidemia	3 (8.6)		2 (5.7)		0
Hyperuricemia	2 (5.7)		3 (8.6)		0
Hypertriglyceridemia	2 (5.7)		1 (2.9)		1 (2.9)
Hypercholesterolemia	0		2 (5.7)		1 (2.9)
Headache	0		2 (5.7)		0
Atopic dermatitis	2 (5.7)		1 (2.9)		0
Leukocytosis	3 (8.6)		0		0

AEs adverse events, TEAEs treatment-emergent adverse events